Un estudio de extensión de Ublituximab en participantes con esclerosis múltiple recurrente
Un estudio de extensión de etiqueta abierta de Ublituximab en sujetos con esclerosis múltiple recurrente
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with RMS. Participants who complete the 96-week, double-blind treatment period of TG1101-RMS301 (RMS301 [NCT03277261]) or TG1101-RMS302 (RMS302 [NCT03277248]) are eligible for participation in this Open Label Extension (OLE) study. Participants may also be eligible for TG1101-RMS303 if they have completed Week 208 of TG1101-RMS201E (RMS201E [NCT03381170]) (United States of America [USA] participants only).
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Grodno, Bielorrusia, 230017
- TG Therapeutics Investigational Trial Site
-
Grodno, Bielorrusia, 320017
- TG Therapeutics Investigational Trial Site
-
Minsk, Bielorrusia, 220114
- TG Therapeutics Investigational Trial Site
-
Minsk, Bielorrusia, 220116
- TG Therapeutics Investigational Trial Site
-
Minsk, Bielorrusia, 220226
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Osijek, Croacia, 31000
- TG Therapeutics Investigational Trial Site
-
Varaždin, Croacia, 42000
- TG Therapeutics Investigational Trial Site
-
Zagreb, Croacia, 10000
- TG Investigational Trial Site
-
-
-
-
California
-
Pasadena, California, Estados Unidos, 91105
- TG Therapeutics Investigational Trial Site
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80045
- TG Therapeutics Investigational Trial Site
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- TG Therapeutics Investigational Trial Site
-
Tampa, Florida, Estados Unidos, 33612
- TG Therapeutics Investigational Trial Site
-
-
Illinois
-
Northbrook, Illinois, Estados Unidos, 60062
- TG Therapeutics Investigational Trial Site
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- TG Therapeutics Investigational Trial Site
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- TG Therapeutics Investigational Trial Site
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- TG Therapeutics Investigational Trial Site
-
-
New Jersey
-
Teaneck, New Jersey, Estados Unidos, 07666
- TG Therapeutics Investigational Trial Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87131
- TG Therapeutics Investigational Trial Site
-
-
New York
-
Amherst, New York, Estados Unidos, 14266
- TG Therapeutics Investigational Trial Site
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43214
- TG Therapeutics Investigational Trial Site
-
Westerville, Ohio, Estados Unidos, 43081
- TG Therapeutics Investigational Trial Site
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37922
- TG Therapeutics Investigational Trial Site
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- TG Therapeutics Investigational Trial Site
-
Frisco, Texas, Estados Unidos, 75034
- TG Therapeutics Investigational Trial Site
-
Round Rock, Texas, Estados Unidos, 78681
- TG Therapeutics Investigational Trial Site
-
San Antonio, Texas, Estados Unidos, 78258
- TG Therapeutics Investigational Trial Site
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Tbilisi, Georgia, 00112
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 00114
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 00159
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 00160
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 00172
- TG Therapeutics Investigational Trial Site
-
Tbilisi, Georgia, 00179
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Katowice, Polonia, 40-555
- TG Therapeutics Investigational Trial Site
-
Katowice, Polonia, 40-568
- TG Therapeutics Investigational Trial Site
-
Katowice, Polonia, 40-684
- TG Therapeutics Investigational Trial Site
-
Krakow, Polonia, 31-505
- TG Therapeutics Investigational Trial Site
-
Lodz, Polonia, 41-800
- TG Therapeutics Investigational Trial Site
-
Olsztyn, Polonia, 10-561
- TG Therapeutics Investigational Trial Site
-
Poznan, Polonia, 61-583
- TG Therapeutics Investigational Trial Site
-
Warsaw, Polonia, 04-141
- TG Therapeutics Investigational Trial Site
-
Zabrze, Polonia, 04-749
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Arkhangelsk, Rusia, 163045
- TG Therapeutics Investigational Trial Site
-
Barnaul, Rusia, 656045
- TG Therapeutics Investigational Trial Site
-
Bryansk, Rusia, 241033
- TG Therapeutics Investigational Trial Site
-
Chelyabinsk, Rusia, 454021
- TG Therapeutics Investigational Trial Site
-
Kemerovo, Rusia, 650066
- TG Therapeutics Investigational Trial Site
-
Krasnoyarsk, Rusia, 660037
- TG Therapeutics Investigational Trial Site
-
Kursk, Rusia, 305007
- TG Therapeutics Investigational Trial Site
-
Moscow, Rusia, 125367
- TG Therapeutics Investigational Trial Site
-
Moscow, Rusia, 127015
- TG Therapeutics Investigational Trial Site
-
Nizhny Novgorod, Rusia, 603155
- TG Therapeutics Investigational Trial Site
-
Novosibirsk, Rusia, 630007
- TG Therapeutics Investigational Trial Site
-
Novosibirsk, Rusia, 630087
- TG Therapeutics Investigational Trial Site
-
Pyatigorsk, Rusia, 357538
- TG Therapeutics Investigational Trial Site
-
Saint Petersburg, Rusia, 197002
- TG Therapeutics Investigational Trial Site
-
Saint Petersburg, Rusia, 197110
- TG Therapeutics Investigational Trial Site
-
Saint Petersburg, Rusia, 197376
- TG Therapeutics Investigational Trial Site
-
Saransk, Rusia, 430032
- TG Therapeutics Investigational Trial Site
-
Smolensk, Rusia, 214018
- TG Therapeutics Investigational Trial Site
-
Tomsk, Rusia, 634050
- TG Therapeutics Investigational Trial Site
-
Tyumen, Rusia, 625000
- TG Therapeutics Investigational Trial Site
-
Ufa, Rusia, 450005
- TG Therapeutics Investigational Trial Site
-
Yekaterinburg, Rusia, 620102
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Belgrade, Serbia, 11000
- TG Therapeutics Investigational Trial Site
-
Kragujevac, Serbia, 34000
- TG Therapeutics Investigational Trial Site
-
-
-
-
-
Cherkasy, Ucrania, 18009
- TG Therapeutics Investigational Trial Site
-
Chernihiv, Ucrania, 14001
- TG Therapeutics Investigational Trial Site
-
Chernihiv, Ucrania, 14029
- TG Therapeutics Investigational Trial Site
-
Chernivtsi, Ucrania, 58002
- TG Therapeutics Investigational Trial Site
-
Ivano-Frankivsk, Ucrania, 76008
- TG Therapeutics Investigational Trial Site
-
Kharkiv, Ucrania, 61058
- TG Therapeutics Investigational Trial Site
-
Kharkiv, Ucrania, 61103
- TG Therapeutics Investigational Trial Site
-
Kharkiv, Ucrania, 61176
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ucrania, 03037
- TG Therapeutics Investigational Trial Site
-
Kyiv, Ucrania, 03115
- TG Therapeutics Investigational Trial Site
-
Lviv, Ucrania, 79000
- TG Therapeutics Investigational Trial Site
-
Lviv, Ucrania, 79010
- TG Therapeutics Investigational Trial Site
-
Odesa, Ucrania, 65009
- TG Therapeutics Investigational Trial Site
-
Poltava, Ucrania, 36011
- TG Therapeutics Investigational Trial Site
-
Ternopil, Ucrania, 46027
- TG Therapeutics Investigational Trial Site
-
Uzhhorod, Ucrania, 88018
- TG Therapeutics Investigational Trial Site
-
Vinnytsia, Ucrania, 21005
- TG Therapeutics Investigational Trial Site
-
Zaporizhia, Ucrania, 69065
- TG Therapeutics Investigational Trial Site
-
Zaporizhia, Ucrania, 96900
- TG Therapeutics Investigational Trial Site
-
Zhytomyr, Ucrania, 10002
- TG Therapeutics Investigational Trial Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Participants must meet the following criteria:
- Complete the 96-week double-blind TG1101-RMS301 (NCT03277261) or TG1101-RMS302 (NCT03277248) study or complete the final Week 208 visit of the TG1101-RMS201E (NCT03381170) study
- Investigator believes may benefit from treatment with ublituximab
- Are able and willing to provide written informed consent (e.g., before the first infusion) and to comply with the study protocol
- Female participants of child-bearing potential, and male partners must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 20 weeks after the last dose of ublituximab
Exclusion Criteria:
Participants who meet any of the following exclusion criteria are not to be enrolled to this study:
-
Any significant or uncontrolled medical condition or treatment-emergent, clinically significant laboratory abnormality such as:
- Absolute neutrophil count < 1.5 x 10e3/µL
- Hematocrit < 24%
- Platelet count < 150,000 cell/mm^3
- Hypogammaglobulinemia immunoglobulin G (IgG) < 4.0g/L
-
Active infection
-
Ongoing pregnancy (female participants)
-
Participants who discontinued ublituximab treatment or withdrew consent from the TG1101-RMS301 or TG1101-RMS302 study during the 96-week evaluation period or prior to completing the final Week 208 visit of the TG1101-RMS201E study
-
Participants who have started any disease modifying therapy (DMT), stem cell transplantation, or participation in any other interventional clinical trial after completion of the 96-week visit in the TG1101-RMS301, TG1101-RMS302, or after completing the final Week 208 visit of the TG1101-RMS201E study
-
Participants who have had a confirmed multiple sclerosis (MS) relapse within the past 30 days prior to Week 1 Day 1 (W1D1). Following a relapse, participants must be neurologically stable for at least 30 days prior to screening or W1D1 of the OLE
-
Participants with unstable disease activity
-
Presence of malignancy, except for surgically excised basal or squamous cell skin lesions
-
Vaccination with live virus within 2 months of randomization
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Ublituximab Infusions
RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312. RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312. For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 312 weeks, or until physician or participant decision to withdraw from the study. |
Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Annualized Relapse Rate (ARR)
Periodo de tiempo: Up to Week 336
|
ARR is defined as the number of relapses per-participant year. The estimate of ARR will be the total number of relapses divided by the sum of duration on study treatment (years). |
Up to Week 336
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- TG1101-RMS303
- 2019-003625-16 (Número EudraCT)
- 2019 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .